2024
Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts
Rivier C, Acosta J, Leasure A, Forman R, Sharma R, de Havenon A, Spatz E, Inzucchi S, Kernan W, Falcone G, Sheth K. Secondary Prevention in Patients With Stroke Versus Myocardial Infarction: Analysis of 2 National Cohorts. Journal Of The American Heart Association 2024, 13: e033322. PMID: 38639369, PMCID: PMC11179946, DOI: 10.1161/jaha.123.033322.Peer-Reviewed Original ResearchMeSH KeywordsAgedAntihypertensive AgentsBlood PressureCross-Sectional StudiesFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMaleMiddle AgedMyocardial InfarctionPlatelet Aggregation InhibitorsPractice Guidelines as TopicRisk AssessmentRisk FactorsSecondary PreventionStrokeUnited KingdomUnited StatesConceptsMyocardial infarctionPrevention scoreSecondary preventionImplementation of preventive therapyNational cohortUK BiobankAntiplatelet therapy useGuideline-directed therapyPrevention profilesBlood pressure controlAdherence to guideline-directed therapyLow-density lipoprotein controlNeighborhood deprivation levelHistory of strokeVascular risk profileStatin useAntiplatelet useTherapy usePreventive therapyComparison to participantsPrevention criteriaCross-sectional analysisBlood pressurePatientsPressure control
2022
Statin Usage Increases White Matter Hyperintensities
Goldstein ED, Garg G, Navarro K, Wolcott Z, Yaghi S, Wong KH, McLean K, de Havenon AH. Statin Usage Increases White Matter Hyperintensities. The Neurologist 2022, 28: 94-98. PMID: 35680399, DOI: 10.1097/nrl.0000000000000448.Peer-Reviewed Original ResearchMeSH KeywordsDisease ProgressionHumansHydroxymethylglutaryl-CoA Reductase InhibitorsMagnetic Resonance ImagingRisk FactorsWhite MatterConceptsWhite matter hyperintensitiesWMH progressionStatin usageTop tertileRisk factorsMatter hyperintensitiesWMH volumeConventional cerebrovascular risk factorsProgression of WMHCerebral small vessel diseaseInfluence of dyslipidemiaCerebrovascular risk factorsInfluence of statinsBaseline WMH volumeSmall vessel diseaseSynergistic risk factorsLow-density lipoproteinFull therapyStatin useVessel diseaseStudy visitWMH developmentPartial therapyWMH dataReductase inhibitors
2019
Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities?
de Havenon A, Prabhakaran S, Turan T, Gottesman R, Yeatts S, Rost N. Is There Equipoise Regarding the Optimal Medical Treatment of Patients with Asymptomatic White Matter Hyperintensities? Journal Of Stroke And Cerebrovascular Diseases 2019, 28: 104371. PMID: 31495669, PMCID: PMC8015436, DOI: 10.1016/j.jstrokecerebrovasdis.2019.104371.Peer-Reviewed Original ResearchMeSH KeywordsAntihypertensive AgentsAsymptomatic DiseasesAttitude of Health PersonnelDisease ProgressionHealth Care SurveysHealth Knowledge, Attitudes, PracticeHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLeukoencephalopathiesNeurologistsPlatelet Aggregation InhibitorsPractice Patterns, Physicians'Therapeutic EquipoiseTreatment OutcomeConceptsAsymptomatic white matter hyperintensitiesWhite matter hyperintensitiesOptimal medical treatmentMatter hyperintensitiesMedical treatmentCognitive impairmentIntensive Blood Pressure ReductionNeurologists' attitudesBlood pressure targetsStroke prevention therapyBlood pressure reductionOptimal medical managementRegional coordinating centersMild cognitive impairmentStatin therapyIschemic strokeMicrovascular diseasePressure targetsPrevention therapyClinical outcomesFunctional disabilityMedical managementPatient populationCommon manifestationWMH progressionSubclinical Cerebrovascular Disease: Epidemiology and Treatment
de Havenon A, Meyer C, McNally JS, Alexander M, Chung L. Subclinical Cerebrovascular Disease: Epidemiology and Treatment. Current Atherosclerosis Reports 2019, 21: 39. PMID: 31350593, PMCID: PMC8011954, DOI: 10.1007/s11883-019-0799-1.Peer-Reviewed Original ResearchMeSH KeywordsAgedAged, 80 and overAspirinAsymptomatic DiseasesBrain InfarctionDementiaFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLeukoaraiosisMagnetic Resonance ImagingMaleMiddle AgedPlatelet Aggregation InhibitorsPrevalenceRisk FactorsStrokeTreatment OutcomeConceptsMedical managementRisk factorsAggressive medical managementSilent brain infarctsOptimal medical treatmentVascular risk factorsDevelopment of dementiaBest medical managementImportant risk factorLate-life depressionCommon clinical scenariosWhite matter hyperintensitiesT2-weighted MRISusceptibility-weighted MRIEvidence-based approachBrain infarctsCerebral microbleedsCerebrovascular diseaseGait instabilityBrain healthClinical equipoiseWorse outcomesClinical trialsMatter hyperintensitiesEpidemiologic studies